No To Five, Yes To Three: NICE Decides On Funding For Drugs In England
NICE To Review Vyndaqel Guidance Quickly If New Pricing Deal Is Reached
Executive Summary
Pfizer has been unsuccessful in its appeal against the health technology assessment body’s rejection of the rare heart disease drug, Vyndaqel. Meanwhile, Dr Falk Pharma has received the all-clear to make Jorveza (budesonide) available on the National Health Service for eosinophilic esophagitis.